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Abstract
BACKGROUND AND OBJECTIVE—Plus disease is the primary indication for retinopathy of 
prematurity (ROP) treatment, but ophthalmologists often struggle to judge whether it is present. 
ROPtool is a semi-automated computer program that objectively assesses plus disease by 
measuring retinal vascular tortuosity and width. This study determined ROPtool’s bedside 
diagnostic accuracy concurrent with ROP screening.
PATIENTS AND METHODS—ROP screening examinations were recorded using Keeler video 
indirect ophthalmoscopy. A masked operator traced images in ROPtool at the bedside, comparing 
ROPtool’s plus diagnosis to the examiner’s clinical judgment.
RESULTS—Four hundred sixty-four examinations (129 eyes of 65 infants) were performed. 
ROPtool’s sensitivity, specificity, and area under the receiver operating characteristic curve for 
plus diagnosis was 71% (CI: 38%–100%), 93% (CI: 89%–98%) and 0.87, and for pre-plus or 
worse was 68% (CI: 51%–85%), 82% (CI: 77%–86%) and 0.81, respectively.
CONCLUSION—ROPtool can provide a real-time second opinion of plus disease at the bedside. 
Image enhancement technologies may further improve ROPtool’s diagnostic accuracy.
INTRODUCTION
Retinopathy of prematurity (ROP) remains an important cause of treatable childhood 
blindness.1 Optimal timing of treatment for severe ROP relies in part on accurate diagnosis 
of plus2–4 and pre-plus5 disease, defined based on the abnormal dilation and tortuosity 
represented by a standard photograph.2 Disagreement on plus and pre-plus disease diagnosis 
is common, even among experienced examiners and experts in the field,6–8 which may lead 
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to inconsistency in diagnosis and treatment among medical centers.9 It would be ideal to 
have objective measures of plus disease to assist with appropriate management of ROP.
ROPtool is a computer program with validated, semi-automated measures of retinal vascular 
dilation and tortuosity, and it can objectively diagnose plus and pre-plus disease from high-
quality RetCam fundus photographs (Clarity Medical Systems, Pleasanton, CA) of infants 
with ROP.10–12 ROPtool has the potential to be useful as a “second opinion.” However, 
prior studies have not assessed ROPtool’s real-time accuracy at the bedside. Previously 
validated for identification of clinically important ROP,13 Keeler wireless digital indirect 
ophthalmoscopy (Keeler Instruments, Broomall, PA) was selected for this study because, in 
contrast to RetCam, it is noncontact, more portable, and significantly less expensive, making 
it more suitable for the developing world, where this technology may be useful. 
Disadvantages include lower image quality, smaller field of view, and the need for operator 
skills in indirect ophthalmoscopy. In this study, ROPtool was used at the bedside to quantify 
plus and pre-plus disease using video indirect ophthalmoscopic still images captured during 




Sixty-five infants undergoing routine ROP examinations were recruited in the neonatal 
intensive care unit at Duke Hospital. Parents or legal guardians of all infants undergoing 
routine ROP examinations were offered enrollment in this institutional review board–
approved study, and informed consent was obtained. Infants could begin participation at any 
time prior to discharge from the hospital.
Reference Standard: Determination of Plus by Clinical Examination
According to standard ROP examination protocol, participants had their pupils dilated using 
a combination eye drop (cyclopentolate 0.2% and phenylephrine 1%). Each infant had 
his/her first examination performed 4 to 6 weeks after birth, following routine screening 
guidelines.14 As usual, infants at risk for progression based on the clinician’s funduscopic 
examination results were monitored more closely (every week) than others (every 2 weeks) 
for the next 3 to 4 months.
During each routine ROP examination, one of two ROP-experienced examiners (SFF or 
DKW) graded each quadrant as plus, pre-plus, or neither, without knowledge of ROPtool’s 
analysis. The overall designation of plus, pre-plus, or neither was based on two or more 
quadrants meeting criteria, consistent with the clinical definition of plus disease.15 The 
infants’ treatment and follow-up were based on the examiner’s clinical findings, consistent 
with standard care.
ROPtool Quantification of Vascular Abnormality
Each examination was videotaped using the Keeler wireless digital indirect ophthalmoscope 
with a 28-diopter condensing lens. Several still fundus images (typically five to 10 per eye) 
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centered on the optic nerve were taken while obtaining video footage. Masked to the clinical 
diagnosis, one researcher (MTC) selected two still images for analysis, based on qualitative 
assessment of best centration and focus. The setting for ROPtool analysis was identical to 
the setting where bedside examinations occurred but in a separate patient room, so that the 
examiner was masked to subject identity, health status, and the results of the clinical eye 
examination. ROPtool software was run by a single operator (MTC) to establish values for 
tortuosity-weighted plus,12 a previously validated measure that combines ROPtool-
generated tortuosity index and dilation index10 into an overall measure of plus disease 
(Figure 1). Tortuosity-weighted plus mathematically accounts for the empiric observation 
that some examiners give dilation more weight as tortuosity increases.12 To calculate 
sensitivity and specificity, ROPtool’s values for tortuosity-weighted plus were converted to 
quadrant-level designations of plus, pre-plus, or neither based on previously chosen 
thresholds from an expert-validated ROPtool study using a selection of borderline plus 
disease enriched high-quality RetCam images.12 Whole-eye designations of plus, pre-plus, 
or neither were based on two or more quadrants meeting criteria, consistent with the clinical 
definition of plus disease.15 The total time required for each image analysis, from opening 
the image file to saving ROPtool’s output, was measured on a stopwatch.
Calculating Image Quality
Image quality determination occurred on a subsequent day, with several days’ still fundus 
images pooled together to minimize recall of ROPtool’s individual image performance. 
Without access to clinical or ROPtool diagnosis, the examiner graded each quadrant on a 
scale from 1 to 4 for factors noted to interfere with ROPtool’s ability to trace images, 
including fundus pigmentation, decentration, vessel blur, vessel obscuration due to glare, 
and vessel obscuration due to shadow (Table 1). For each image’s composite quality score, 
the lowest quadrant image quality (based on the sum of quadrant scores, excluding fundus 
pigmentation) was calculated on a scale from 4 to 16 (25% to 100%) to estimate its impact 
on ROPtool’s functionality.
Statistical Analysis
ROPtool’s traceability was defined as at least one vessel traced in all four quadrants for a 
distance of at least one disc diameter, as described previously.12,16 Among the best-quality 
traceable images, ROPtool’s sensitivity and specificity for assessment of plus and pre-plus 
disease were calculated, using the examiner’s clinical bedside diagnosis as the reference 
standard. Predetermined cut points for plus and pre-plus disease were used for this analysis, 
based on previous ROPtool validation with three-expert consensus analyzing high-quality 
RetCam photographs.12 Logistic regression was used to determine the influence of clinical 
and demographic parameters on ROPtool’s diagnostic agreement with the examiner.
Receiver operating characteristic curves were generated at the quadrant level using varying 
cut points of tortuosity-weighted plus values for both plus and pre-plus or worse diagnosis to 
generate sensitivity on the y-axis and 1-specificity on the x-axis, with the examiner 
diagnosis as the reference standard.
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For all of the above calculations, generalized estimating equations were used to account for 




In total, 464 examinations of 129 eyes of 65 premature infants (33 white, 28 black, and two 
Hispanic) were performed. Median gestational age was 26 weeks (range: 23 to 34 weeks), 
and median birth weight was 850 g (range: 473 to 1,660 g). Median number of visits per 
infant was three (range: 1 to 12). Median postmenstrual age at the time of examination was 
36 weeks (range: 30 to 58 weeks). Among those with complete clinical fundus evaluation, 
plus disease was present in 16 of 462 examinations (3.5%) and six of 65 infants (9.2%), and 
pre-plus was present in 38 of 462 examinations (8.2%) and 14 of 65 infants (21.5%).
ROPtool’s Performance at the Bedside
The median composite image quality score among all best images was 81% (13/16; range: 
7/16 to 16/16, or 44% to 100%). Eighty-two percent (380/464, CI: 76% to 88%) of these 
images were traceable by ROPtool. Of these, two clinical diagnoses were indeterminate 
because the examiner did not observe any major vessels in one quadrant, although ROPtool 
was able to trace a thin vessel in that quadrant. Among images with both ROPtool 
traceability and a clinical diagnosis, 15 of 378 (4.0%) had a clinical diagnosis of plus disease 
and 36 of 378 (9.5%) had a clinical diagnosis of pre-plus disease. Traceable images had a 
significantly higher image quality score compared to non-traceable images (median: 13/16 
or 81%, compared to 11/16 or 69%, respectively; P < .001). Median time to complete each 
ROPtool analysis of traceable images was 2.2 minutes (range: 1 to 7.25 minutes).
To determine ROPtool’s reproducibility at the bedside, quadrants from two different 
traceable video still images taken from the same imaging session were analyzed; agreement 
for plus disease diagnosis was 92% (CI: 90% to 93%) and 77% (CI: 75% to 80%) for pre-
plus or worse.
Comparing ROPtool and Clinical Examiner’s Diagnosis as Reference Standard
When using the examiner’s diagnosis as the reference standard, the area under the receiver 
operating characteristic curve was 0.87 for diagnosing plus disease (Figure 2A) and 0.81 for 
diagnosing pre-plus or worse disease (Figure 2B). Using predetermined cut points from a 
previous study,12 ROPtool’s sensitivity and specificity for diagnosing plus disease was 
10/14 or 71% (CI: 38% to 100%) and 337/361 or 93% (CI: 89% to 98%), and pre-plus 
disease was 34/50 or 68% (CI: 51% to 85%) and 265/325 or 82% (CI: 77% to 86%), 
respectively. Younger infant age at the time of examination (P = .014) and lower ROP stage 
(P = .006) were significantly associated with better diagnostic agreement between ROPtool 
and the examiner (Table 2). Sex, race, gestational age, weight, right or left eye, pupil size, 
ventilation status, identity of examiner, zone of disease, laser history, image quality, and 
retinal pigmentation were not associated with diagnostic agreement between ROPtool and 
the examiner (Table 2).
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Availability of experienced providers to meet the needs of the community may be 
inadequate in some regions of the United States and certainly in developing countries.17 
Furthermore, ophthalmologists treating ROP are confronted with the subjective nature of 
stage, zone, and plus disease diagnosis,2 which may result in over- or under-treatment.9 
Identification of plus disease in particular often predicts treatment.2 Objective assistance 
with ROP diagnosis, including plus disease, would be ideal to address both the shortage of 
experienced examiners (via a telemedicine approach) and the inaccuracies of the bedside 
diagnosis.
Advantages of ROPtool include speed (median time to execute was just over 2 minutes) and 
good reproducibility. However, the diagnostic agreement between Keeler video indirect 
ophthalmoscopic images and an experienced examiner did not compare favorably to 
findings of a prior study12 assessing ROPtool using RetCam images selected for high 
quality. We observed sensitivity, specificity, and area under the receiver operating 
characteristic curve of 71%, 93%, and 0.87, respectively, compared to 85%, 85%, and 0.94 
in the previous study.12 Although the magnification of the video indirect images in the 
present study differed from that of RetCam images used previously, ROPtool software 
accounts for magnification in its calculations.10
The present study has greater relevance to ROPtool’s real-world application at the bedside; 
however, one explanation for our lower sensitivity and area under the receiver operating 
characteristic curve is the inferior quality of still images taken during video indirect fundus 
photography (vs selection of only high-quality RetCam photographs in the prior study). 
Lower-quality video indirect photographs may have resulted in overall changes in 
ROPtool’s measurements; for example, image blurring can make a vessel look wider and 
cause ROPtool to overestimate retinal vascular thickness. As expected, lower image quality 
contributed to poor traceability because nontraceable images had lower image quality 
compared to traceable images. ROPtool was able to successfully trace only 82% of video 
indirect images (compared to 100% of high quality RetCam images previously12). It is 
possible that a 20- rather than 28-diopter condensing lens would have resulted in higher-
quality images. Nonetheless, the 28-diopter lens is preferred by many ROP examiners due to 
its wider field of view.
Our point estimates of ROPtool’s reproducibility and agreement with the examiner were 
both less favorable for diagnosing pre-plus compared to plus disease. Pre-plus is more 
subjectively defined (abnormal dilation and tortuosity but less than the standard plus disease 
photograph).15 Therefore, the examiner’s diagnosis may be less consistent, leading to less 
agreement with ROPtool. Furthermore, because pre-plus values are lower than plus values, 
errors of similar magnitude in ROPtool’s measurements may have been magnified because 
they represented larger percentages of the tortuosity-weighted plus value.
One possible limitation of this study is that the examiner’s bedside diagnosis may be 
inaccurate. Previous studies have shown that experts and experienced examiners often 
disagree on the diagnosis of plus and pre-plus disease.6–8 We considered using an alternative 
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reference standard based on three-expert consensus interpretation of ophthalmoscopic 
videos. However, unlike RetCam images, expert interpretation of Keeler ophthalmoscopic 
video has not been validated previously and therefore cannot be considered a reliable 
reference standard. This study’s level of agreement in the diagnosis of plus disease between 
ROPtool and each examiner (SFF vs DKW) was similar (90% vs 95%; P = .22) (Table 2). 
Furthermore, studies that guide current treatment criteria, such as Supplemental Therapeutic 
Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP)18 and Early Treatment 
for Retinopathy of Prematurity (ETROP),3 were based on the examiner’s clinical diagnosis. 
Therefore, the examiner’s clinical diagnosis remains the gold standard.
This study must be viewed in light of some additional limitations. Plus disease was graded 
by examiners at the quadrant level, which is not the typical way of diagnosing plus disease 
in the clinical setting. Nonetheless, quadrant-level diagnosis allowed for construction of 
more accurate receiver operating characteristic curves, because it increased the number of 
observations fourfold. Furthermore, quadrant -evel diagnosis is relevant to current 
diagnostic criteria, which stipulate that at least two quadrants must have sufficient 
abnormality to diagnose plus disease.15 Whole-eye diagnoses were extrapolated and used for 
all other analyses. If ROPtool’s thresholds for plus and pre-plus disease were based on video 
images rather than RetCam images from prior studies,12 it is possible that ROPtool’s 
performance in this study would have improved. Nonetheless, we decided to use RetCam 
image interpretation from prior studies12 for cut point selection because video indirect image 
interpretation is not a well-established standard. This study was also limited by lack of 
validation of ROPtool with a second ROPtool operator. However, ROPtool inter-operator 
validation has been performed previously with 95% concordance.19
There are challenges worldwide to delivering care to infants with retinopathy of prematurity, 
as fewer ophthalmologists are able and willing to evaluate and treat the disease, while a 
higher proportion of premature infants survive to warrant ROP screening.20 This study 
demonstrates that ROPtool’s utility as a clinical adjunct for ROP diagnosis with current 
video indirect imaging shows promise, but it cannot be considered a highly accurate second 
opinion at the bedside yet. Image enhancement technologies,21,22 advancements in video 
indirect image quality, use of RetCam instead of video indirect ophthalmoscopy, and 
adjustments in ROPtool’s pre-plus and plus thresholds may improve ROPtool’s future 
performance at the bedside, and these modifications deserve further study.
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Example of ROPtool’s desktop user interface. ROPtool’s computer-assisted tracing of a 
retinal still image from video indirect ophthalmoscopy of an infant with retinopathy of 
prematurity is shown, with output of each quadrant’s tortuosity index and dilation index. 
Calculations of plus disease by sum of adjusted indices and tortuosity-weighted plus (TWP) 
are shown. The current study used TWP for all analyses.
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Receiver operating characteristic curve for ROPtool computer program’s diagnosis of plus 
disease (A) and pre-plus disease (B) or worse, with the examiner’s clinical diagnosis as the 
reference standard.
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TABLE 1
Image Quality Measures and Score Definitions
Image Characteristic* Score 1 Score 2 Score 3 Score 4
Fundus pigmentation Light Medium Dark
Decentration Entire quadrant missing or less 
than or equal to 1 disc 
diameter of length of major 
vessels present in quadrant or 
center of macula missing from 
whole eye image.
Between 1 and 2 disc 
diameters of length of 





size or enlarged 
quadrant size due 
to decentration.
Vessel blur Extremely distorted image 
quality due to defocus.
Substantial blurring of 
vessels.
Slight blurring of vessel 
margins.
Sharp or almost 
sharp vessel 
margins.
Vessel obscuration due to 
glare
Vessels almost completely 
obscured under diffuse mild to 
moderate glare or substantial 
glare takes up greater than half 
of the quadrant.
Vessels moderately 
obscured under diffuse 
mild glare or substantial 
glare takes up greater than 
a quarter and less than half 
of the quadrant.
Mild glare takes up most 
of the quadrant and 
vessels not noticeably 
obscured or substantial 
glare takes up less than a 
quarter of the quadrant.
No glare.
Vessel obscuration due to 
shadow
Vessels almost completely 
obscured under diffuse mild to 
moderate shadow or 
substantial shadow takes up 
greater than half of the 
quadrant.
Vessels moderately 
obscured under diffuse 
mild shadow or substantial 
shadow takes up greater 
than a quarter and less than 
half of the quadrant.
Mild shadow takes up 
most of the quadrant but 
vessels not noticeably 
obscured or substantial 
shadow takes up less than 
a quarter of the quadrant.
No shadow.
*
Image quality was graded in each quadrant for these characteristics. A composite image quality score was calculated from the sum of 
decentration, vessel blur, vessel obscuration due to glare, and vessel obscuration due to shadow scores.
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TABLE 2




Plus Diseasea (n = 28)
Agreement for
Plus Diseasea (n = 347) P Value
Gender
717  Male N (%) 9 (7) 129 (93)
  Female N (%) 19 (8) 218 (92)
Raceb
.112  White N (%) 22 (10) 199 (90)
  Black N (%) 5 (4) 137 (96)
Gestational age in weeks Median (range) 25 (23–28) 26 (23–34) .160
Weight in grams Median (range) 785 (473–1110) 840 (473–1660) .259
Age in postmenstrual weeks Median (range) 38.5 (34–53) 36 (30–58) .014c
Eye
.051  Right N (%) 19 (10) 177 (90)
  Left N (%) 9 (5) 170 (95)
Pupild Median (range) 6 (4–8) 7 (2–9) .281
Ventilation status
.779
  No oxygen N (%) 18 (7) 223 (93)
  Nasal cannula N (%) 5 (6) 72 (94)
  CPAP N (%) 3 (8) 35 (92)
  Intubated N (%) 1 (1) 8 (89)
Examiner
.222  SFF N (%) 18 (10) 157 (90)
  DKW N (%) 10 (5) 190 (95)
Stage of retinopathy of prematurity
.006c
  0 N (%) 3 (3) 104 (97)
  1 N (%) 2 (3) 61 (97)
  2 N (%) 9 (6) 136 (94)
  3 N (%) 13 (25) 39 (75)
Zone of retinopathy of prematurity .134
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Variable Statistic
No Agreement for
Plus Diseasea (n = 28)
Agreement for
Plus Diseasea (n = 347) P Value
  1 N (%) 2 (6) 30 (94)
  2 N (%) 22 (8) 242 (92)
  3 N (%) 2 (3) 62 (97)
 Fully vascularized N (%) 0 6 (100)
Laser prior to exam
.122  No N (%) 18 (5) 316 (95)
  Yes N (%) 10 (24) 31 (76)
Image quality scoree Median (range) 13.5 (9–15) 13 (9–16) .536
Fundus pigmentation
.308
  Light N (%) 16 (13) 109 (87)
  Medium N (%) 8 (5) 141 (95)
  Dark N (%) 4 (4) 97 (96)
a
Frequencies in subcategories may not sum to the totals due to missing data.
b
Hispanics not included here because group was too small.
c




A composite image quality score for the worst quadrant from each fundus image used in ROPtool, which is the sum of scores for decentration, 
vessel blur, vessel obscuration due to glare, and vessel obscuration due to shadow; lower scores represent lower quality
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